From a cellular medicinal viewpoint, Relafen 750 (naproxen sodium) signifies a compelling case study in noncopyrightal anti-inflammatory drug action. Its mechanism of diminishing inflammation and discomfort copyrights primarily on the inhibition of cyclooxygenase (COX) proteins , specifically COX-1 and COX-2. Examining the selective aspects of this